| Prev Close | 1.13 |
| Open | 1.15 |
| Day Low/High | 1.12 / 1.15 |
| 52 Wk Low/High | 0.71 / 2.25 |
| Volume | 337.72K |
| Avg Volume | 536.20K |
| Exchange | NASDAQ |
| Shares Outstanding | 104.10M |
| Market Cap | 117.63M |
| EPS | -0.30 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
BioLineRx Announces Initiation Of Phase 1b/2 Trial Of BL-8040 In Pancreatic Cancer Under Immunotherapy Collaboration
Combination trial of BL-8040 and atezolizumab are part of initiative for the development of novel cancer immunotherapy combinations
BioLineRx Announces Regulatory Submission For Phase 1b Trial Of BL-8040 In Combination With Atezolizumab In AML
Phase 1b trial under cancer immunotherapy collaboration with Genentech
BioLineRx To Report First Quarter 2017 Results On May 25, 2017
Management to hold a conference call at 10:00 a.m. EDT
BioLineRx Announces Acquisition Of Agalimmune Ltd. To Accelerate Expansion Of Immuno-Oncology Pipeline
Agalimmune's Lead Asset, AGI-134, Provides a Unique Approach for Eliciting Patient-specific, Anti-tumor Immune Responses in Multiple Cancer Types
BioLineRx To Report Annual 2016 Results On March 23, 2017
Management to hold a conference call at 9:00 a.m. EDT
BioLineRx (BLRX) Stock Soars on Liver Drug Licensing Agreement
BioLineRx (BLRX) signed a licensing agreement with two Israeli companies to allow the development of a drug that treats liver failure conditions.
7 Stocks Under $10 to Trade for Big Profits
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
7 Stocks Under $10 Making Big Moves
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
BioLineRx Announces Regulatory Submission For Phase 2 Trial Of BL-8040 As Novel Stem Cell Mobilization Treatment
BioLineRx Ltd. (NASDAQ/TASE:BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today the filing of regulatory submissions...
BioLineRx Establishes Oncology Scientific Advisory Board
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reported the establishment of a Scientific...
BioLineRx Ltd. To Host Investor Breakfast In New York On December 3, 2015
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today announced that it will host an investor breakfast...
BioLineRx To Present At The LD Micro Main Event
BioLineRx Ltd. (NASDAQ, TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer,...
BioLineRx Reports Third Quarter 2015 Financial Results
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reported its financial results for the third...
BioLineRx To Report Third Quarter 2015 Results On November 16, 2015
BioLineRx Ltd. (NASDAQ, TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it will release its unaudited...
BioLineRx Announces Positive Clinical Results From First Part Of Phase 2 Trial In R/r AML
BioLineRx Ltd. (NASDAQ, TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today positive results from the dose...
BioLineRx's Novel Treatment For Non-Surgical Removal Of Skin Lesions Submitted For CE Mark Registration
BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its partner, Omega Pharma,...
BioLineRx To Present At The 17th Annual Rodman & Renshaw Global Investment Conference In New York
BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer,...
BioLineRx Reports Second Quarter 2015 Financial Results
BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reported its financial results for the...
BioLineRx Announces Initiation Of Phase 2b Trial For Novel AML Consolidation Treatment
BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today the initiation of a Phase 2b...
BioLineRx To Report Second Quarter 2015 Results On August 20, 2015
BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it will release its...
BioLineRx (BLRX) Stock Down on Negative Heart Disease Treatment Results
BioLineRx (BLRX) shares are down by almost 20% after the company confirmed weak results from its placebo-controlled heart disease treatment tests.
